Exchange: NYSE·Updated 09:56 AM EDT
News
all
press releases
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?
Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.
Zacks
Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?
STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
Zacks
Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.
Zacks
Should You Hold Edwards Lifesciences Stock in Your Portfolio?
EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.
Zacks
Here's How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.93% on an annualized basis producing an average annual return of 17.22%. Currently, Edwards Lifesciences has a market capitalizationread more...
Benzinga
Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?
Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.
Zacks
$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.31% on an annualized basis producing an average annual return of 15.06%. Currently, Edwards Lifesciences has a market capitalizationread more...
Benzinga
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.
Zacks
Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?
Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.
Zacks

Advertisement|Remove ads.